Evidence map›Paper›PMID 40218932›Full record

ReviewNutrients2025

Targeting Bile-Acid Metabolism: Nutritional and Microbial Approaches to Alleviate Ulcerative Colitis.

Xiaoxin Jiang, Jingyi Ren, Gejun Yu, Wentao Wu, Mengyuan Chen, Yun Zhao, Canxia He

Abstract readReview
In one paragraph

Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoxin JiangSchool of Public Health, Health Science Center, Ningbo University, Ningbo 315211, China.
Jingyi RenSchool of Public Health, Health Science Center, Ningbo University, Ningbo 315211, China.
Gejun YuSchool of Public Health, Health Science Center, Ningbo University, Ningbo 315211, China.
Wentao WuSchool of Public Health, Health Science Center, Ningbo University, Ningbo 315211, China.
Mengyuan ChenSchool of Public Health, Health Science Center, Ningbo University, Ningbo 315211, China.
Yun ZhaoSchool of Public Health, Health Science Center, Ningbo University, Ningbo 315211, China.
Canxia HeSchool of Public Health, Health Science Center, Ningbo University, Ningbo 315211, China.ORCID 0000-0002-2017-8004

Funding

National Natural Science Foundation of China 82103819
6 · The paper itself

Abstract

Ulcerative colitis (UC) is a chronic inflammatory disease affecting the colorectum, posing a significant global health burden. Recent studies highlight the critical role of gut microbiota and its metabolites, particularly bile acids (BAs), in UC's pathogenesis. The relationship between BAs and gut microbiota is bidirectional: microbiota influence BA composition, while BAs regulate microbiota diversity and activity through receptors like Farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5). Targeting bile-acid metabolism to reshape gut microbiota presents a promising therapeutic strategy for UC. This review examines the classification and synthesis of BAs, their interactions with gut microbiota, and the potential of nutritional and microbial interventions. By focusing on these therapies, we aim to offer innovative approaches for effective UC management.

Indexed as

Bile Acids and SaltsColitis, UlcerativeGastrointestinal MicrobiomeAnimalsHumansReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearReceptors, G-Protein-CoupledBile Acids and SaltsReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearReceptors, G-Protein-Coupledbile acidsmicrobiotanutritionulcerative colitis

Identifiers

PMID40218932
PMCPMC11990178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.